EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Integrated Engineering of CAR ‐T Cells for Solid Tumours

Chao Yang, Tan Li, Ping He, Zhijie Zhao iD, Shenglong Li iD, Liming Wang iD

Cell Proliferation · 2026-09 · 59 (9)

DOI: 10.1111/cpr.70263 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cell Proliferation, online erschienen am 14.07.2026. Verfasst von Chao Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Trauma Center and Department of Burns, The First Hospital of China Medical University, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: Neoplasms, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 236 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Liaoning Province, China Health & Medical Development Foundation, Medical Science Research Fund of Beijing Medical and Health Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T‐cell therapy has achieved durable efficacy in hematologic malignancies but encounters persistent obstacles in solid tumours, including antigen heterogeneity, a suppressive tumour microenvironment (TME), and intrinsic T‐cell dysfunction. This review examines the transition from single‐axis engineering to an integrated framework that addresses these hurdles in sequence. We delineate how next‐generation CAR‐T cells are designed for precise spatiotemporal activation through logic‐gated and pharmacologically regulatable receptors, while being reinforced by metabolic and epigenetic reprogramming to resist TME‐driven exhaustion. We also assess strategies that actively reshape the immunosuppressive TME, including depletion of regulatory cell populations, blockade of ‘don't eat me’ signals, and the use of biomaterial scaffolds for locoregional delivery. The synthesis of controllable activation, intrinsic resilience, and extrinsic TME modulation is defining a class of adaptive therapeutic systems. Clinical implementation of this approach requires careful management of toxicities, notably cytokine release syndrome (CRS), and support from advanced monitoring technologies. Progress will depend on rational combinations that move beyond isolated optimisations, enabling cellular therapies to dynamically respond to evolving tumour ecosystems and narrowing the efficacy gap between hematologic and solid cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsReceptors, Chimeric AntigenImmunotherapy, AdoptiveT-LymphocytesHumansTumor MicroenvironmentAnimalsT-Cell Exhaustion

Stichwörter der Autor:innen

CAR‐T cellmetabolic reprogrammingregional deliverysolid tumourstumour microenvironment (TME)

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Trauma Center and Department of Burns, The First Hospital of China Medical University, Shenyang, Liaoning, China.
  • Department of Cardiovascular Ultrasound, The First Hospital of China Medical University, Shenyang, Liaoning, China.
  • Department of Laboratory Medical Center, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
  • Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Second Ward of Bone and Soft Tissue Tumor Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China.
  • Department of Thoracic Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.

ORCID-Profile: Zhijie Zhao, Shenglong Li, Liming Wang

Förderung

  • Natural Science Foundation of Liaoning Province
  • China Health & Medical Development Foundation
  • Medical Science Research Fund of Beijing Medical and Health Foundation

Zitieren

APA

Yang, C., Li, T., He, P., Zhao, Z., Li, S., & Wang, L. (2026). Integrated Engineering of CAR ‐T Cells for Solid Tumours. Cell Proliferation, 59(9). https://doi.org/10.1111/cpr.70263

Vancouver

Yang C, Li T, He P, Zhao Z, Li S, Wang L. Integrated Engineering of CAR ‐T Cells for Solid Tumours. Cell Proliferation. 2026;59(9). doi:10.1111/cpr.70263

BibTeX
@article{Yang2026,
  author = {Yang, Chao and Li, Tan and He, Ping and Zhao, Zhijie and Li, Shenglong and Wang, Liming},
  title = {Integrated Engineering of CAR ‐T Cells for Solid Tumours},
  journal = {Cell Proliferation},
  year = {2026},
  volume = {59},
  number = {9},
  doi = {10.1111/cpr.70263}
}
Kostenlos starten →